These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35715644)

  • 1. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial.
    Castellarnau A; Heery GP; Seta A; Luscombe CA; Kinghorn GR; Button P; McCloud P; Paull JRA
    Sci Rep; 2022 Jun; 12(1):10210. PubMed ID: 35715644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial.
    Winchester S; Castellarnau A; Jabbar K; Nadir M; Ranasinghe K; Masramon X; Kinghorn GR; John I; Paull JRA
    Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
    Paull JRA; Heery GP; Bobardt MD; Castellarnau A; Luscombe CA; Fairley JK; Gallay PA
    Antiviral Res; 2021 Jul; 191():105089. PubMed ID: 34010661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium.
    Paull JRA; Luscombe CA; Seta A; Heery GP; Bobardt MD; Gallay PA; Constant S; Castellarnau A
    Sci Rep; 2024 Sep; 14(1):21259. PubMed ID: 39261670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
    Chavoustie SE; Carter BA; Waldbaum AS; Donders GGG; Peters KH; Schwebke JR; Paull JRA; Price CF; Castellarnau A; McCloud P; Kinghorn GR
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():13-18. PubMed ID: 31812702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.
    Waldbaum AS; Schwebke JR; Paull JRA; Price CF; Edmondson SR; Castellarnau A; McCloud P; Kinghorn GR
    PLoS One; 2020; 15(5):e0232394. PubMed ID: 32365097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
    Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
    Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients.
    De Boeck I; Cauwenberghs E; Spacova I; Gehrmann T; Eilers T; Delanghe L; Wittouck S; Bron PA; Henkens T; Gamgami I; Simons A; Claes I; Mariën J; Ariën KK; Bakokimi D; Loens K; Jacobs K; Ieven M; Bruijning-Verhagen P; Delputte P; Coenen S; Verhoeven V; Lebeer S
    Microbiol Spectr; 2022 Oct; 10(5):e0168222. PubMed ID: 36154666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.
    Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK
    Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.